About 7,228 results

ALLMedicine™ Cardiogenic Shock Center

Research & Reviews  2,600 results

Rescue extracorporeal life support as a bridge to durable left ventricular assist device.
The International Journal of Artificial Organs; Zubarevich A, Zhigalov K et. al.

Oct 23rd, 2021 - The ideal timing of a durable assist device implantation in patients with end-stage heart failure presenting with INTERMACS profile I is still controversial. The data on extracorporeal life support (ECLS) bridge to durable left ventricular assist ...

Increased and continuous coronary arterial flow was induced by LV uncoupling condition ...
Physiological Reports; Kametani M, Yamada M et. al.

Oct 23rd, 2021 - An emerging therapeutic modality, ECPELLA, which combines a transvalvular microaxial left ventricular (LV) assist device, Impella, and venoarterial membrane oxygenation (VA-ECMO), has been applied for patients with refractory cardiogenic shock. Du...

Sjögren-related cardiomyopathy presenting with cardiogenic shock.
BMJ Case Reports; Al Turk Y, Lemor A et. al.

Oct 21st, 2021 - Previous reports have described non-ischaemic cardiomyopathy related to a variety of autoimmune diseases. However, very few case reports describe Sjögren disease as a contributing factor to cardiomyopathy. We report the case of a 69-year-old woman...

Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of...
ESC Heart Failure; Radu RI, Ben Gal T et. al.

Oct 20th, 2021 - Cardiogenic shock (CS) is a complex multifactorial clinical syndrome, developing as a continuum, and progressing from the initial insult (underlying cause) to the subsequent occurrence of organ failure and death. There is a large phenotypic variab...

Myocarditis as an immune-related adverse event following treatment with ipilimumab and ...
Journal of Medical Case Reports; Miyauchi Y, Naito H et. al.

Oct 16th, 2021 - Immune checkpoint inhibitors are new immunotherapy drugs globally used for many malignancies, including renal cell carcinoma. Myocarditis as an immune-related adverse event is rare but highly fatal, suggesting that its frequency may be higher than...

see more →

Drugs  41 results see all →

Clinicaltrials.gov  37 results

ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock

Sep 8th, 2021 - Eligible patients with severe cardiogenic shock will be randomized to one of the two arms: immediate ECMO therapy or early conservative therapy. In the invasive group, veno-arterial ECMO will be implanted according to the local practice with flow ...

Mechanical Complications of Acute Myocardial Infarction During COVID-19 Pandemics

Sep 5th, 2021 - Mechanical complications must be carefully searched for in any patient with an acute coronary syndrome and signs of cardiogenic shock, as prompt diagnosis and immediate surgery often represent the only effective treatment for such ominous conditio...

ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock

Aug 30th, 2021 - The prospective, interventional, randomised controlled and blinded ECMOsorb study investigates in critically ill patinets with cardiogenic shock and with veno-arterial ECMO (VA-ECMO) treatment the impact of an extracorporeal cytokin hemadsorption ...

Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction

Aug 20th, 2021 - Reperfusion therapy for acute ST segment elevation myocardial infarction (STEMI) can significantly reduce mortality, but patients may still have heart failure and adverse cardiovascular events due to massive myocardial loss. About 20% of patients ...

Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock

Aug 4th, 2021 - Randomization: Patients will be randomized in the 6 hours following ECMO start in the normoxemia or in the hyperoxemia group. Randomization will be stratified on center, and medical or postcardiotomy indication for ECMO. Description of experimenta...

see more →

News  211 results

New Reports Help Nail Down Myocarditis Risk With COVID-19 Vaccine

Oct 8th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. This week's literature features new descriptions of myocarditis linked to the two available mRNA vaccines against SARS-CoV-2. They tell a story la...

Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC

Oct 6th, 2021 - Robert C. Doebele, MD, PhD Treatment with entrectinib (Rozlytrek) led to an overall response rate (ORR) of 77% and a median duration of response (DOR) of 24.6 months in patients with ROS1 fusion—positive non–small cell lung cancer (NSCLC), accord...

Cardiogenic Shock Teams Again Tied to Lower Mortality

Sep 21st, 2021 - A large multicenter study provides further evidence supporting the rationale for multidisciplinary teams for cardiogenic shock, one of the most lethal diseases in cardiovascular medicine. The analysis of 24 critical care ICUs (CICUs) in the Critic...

No Win for Milrinone Over Dobutamine in Cardiogenic Shock

Aug 6th, 2021 - A head-to-head randomized comparison of milrinone and dobutamine — the most used inotropes in cardiogenic shock therapy in North America — failed to find a significant advantage for one agent over the other. Patients treated with milrinone and dob...

ISCHEMIA Trial Population Reflects Small Slice of US Practice

May 12th, 2021 - Although the ISCHEMIA trial is a touchstone in the management of patients with stable ischemic heart disease (SIHD), its population does not reflect most patients seen in US practice today, new research suggests. The 2019 landmark trial challenged...

see more →

Patient Education  2 results see all →